Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of LATUDA® (lurasidone HCl) tablets for your patients

ORDER YOUR SAMPLES NOW

Need support? Ask Sunovion Answers for information about LATUDA® (lurasidone HCl)

 

A dedicated team is available 7 days a week, from 8 AM to 12:00 midnight ET, to answer patient's calls at 1-855-552-8832

LEARN MORE

Most Viewed

Patient Profiles

Help your patients with bipolar depression experience more of life's everyday moments.

*Not an actual patient. The Licensed Material is being used for illustrative purposes only. Any person depicted in the Licensed Material, if any, is a model.


Learn more about the types of patients in your practice that may be appropriate for treatment with LATUDA

Click on the patient's photos below to learn more about who they are and how they are currently dealing with their bipolar depression.

Overview
maya-profile

"I feel so disconnected from the people and things I know that I love."

  • Female, age 33
  • Self-employed; longtime ceramics hobby
  • Married with 1 child
History
maya-profile

History

  • Patient reports mood and energy problems since early adulthood, but for years attributed them to having "an artistic temperament"
  • Recently diagnosed with bipolar I disorder (9 months ago)
  • Comorbid conditions: insomnia, history of substance abuse
  • Previous treatment: various antidepressants
  • Current medications: SSRI and anxiolytic
Presentation
maya-profile

Presentation

  • Chief complaints: lack of interest and energy in daily activities; family and work relationships have become strained
  • Feels bad about not spending more time with her daughter and husband
  • Husband reports that patient’s mood shifts have become shorter and more frequent
Overview
Lisa_lg

“When I feel depressed, I want to be alone. I’m afraid of being vulnerable in front of the world.”

  • Female, age 32
  • Stay-at-home mom
  • Married with 2 children
History
Lisa_lg

History

  • Diagnosed with postpartum depression following birth of her first child (10 years ago)
  • Diagnosed with major depressive episodes associated with bipolar I disorder 5 years ago, after an episode of postpartum psychosis following the birth of her second child
  • Comorbid conditions: anxiety, hypothyroidism, type 2 diabetes, BMI 26
  • Previous medications: antidepressant, mood stabilizer
  • Current medications: mood stabilizer, levothyroxine, metformin
Presentation
Lisa_lg

Presentation

  • Chief complaint: frequent depressive episodes, with premenstrual exacerbation
    • Husband reports patient is frequently withdrawn from friends and family and will isolate herself for days at a time
Overview
Craig_lg

"I don’t want to go anywhere, see anyone, or do anything.'"

  • Male, age 37
  • IT professional and part-time student
  • Living with fiancée
History
Craig_lg

History

  • Diagnosed with major depressive disorder (8 years ago)
  • Diagnosed with major depressive episodes associated with bipolar I disorder 3 years ago; previously hospitalized for manic episodes and related substance abuse
  • Comorbid conditions: hyperlipidemia and hypertension, BMI 33
  • Previous medications: multiple SSRIs, mood stabilizers
  • Current medications: patient reports he has stopped taking all medication (doesn't like the way it makes him feel)
Presentation
Craig_lg

Presentation

  • Brought to emergency department by fiancée after missing 4 consecutive days of work due to extreme fatigue and a disinterest in usual daily activities
  • Chief complaints: extreme feelings of worthlessness and inability to think and concentrate
    • Fiancée reports patient's behavior "has never been this bad"
Overview
Jimmy_lg

“It’s hard being down."

  • Male, age 28
  • War veteran
  • Married with 2 children
History
Jimmy_lg

History

  • Diagnosis of bipolar I disorder 6 years ago
  • Comorbid conditions: anxiety (controlled with medication) with a history of substance abuse
  • Previous medications: multiple antidepressants, mood stabilizers, antipsychotics, benzodiazepine
  • Current medications: patient reports that he has stopped taking medication
Presentation
Jimmy_lg

Presentation

  • Severe depressive symptoms led wife to bring him in to facility for evaluation
  • Chief complaints: doesn’t like the way medication makes him feel, isn’t able to concentrate at work
    • Wife complains he is aggravated and temperamental

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behavior. LATUDA is not approved for use in pediatric patients with depression.

 

CONTRAINDICATIONS: LATUDA is contraindicated in the following:

Cerebrovascular Adverse Reactions, Including Stroke: In clinical trials, elderly subjects with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex, reported with administration of antipsychotic drugs. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of antipsychotic drugs, including LATUDA, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes Atypical antipsychotic drugs have caused metabolic changes including:

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Monitor complete blood count in patients with a pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) or history of drug-induced leukopenia/neutropenia. Discontinue LATUDA at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest at the beginning of treatment and when increasing the dose. Monitor patients vulnerable to hypotension and those with cardiovascular and cerebrovascular disease.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls causing fractures or other injuries. For patients with disease, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold.

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Use LATUDA with caution in patients who may experience conditions that increase body temperature (e.g., exercising strenuously, exposure to extreme heat, concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Antipsychotics, including LATUDA, have been associated with esophageal dysmotility and aspiration, and should be used with caution in patients at risk for aspiration pneumonia.

Most Commonly Observed Adverse Reactions: Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA:

To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 877-737-7226 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Indications

LATUDA is indicated for:

Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warnings.